Abstract Stromal cell-derived factor 1-alpha (SDF) is a potent bone marrow chemokine capable of recruiting circulating progenitor populations to injured tissue. SDF has known angiogenic capabilities, but bone marrow-derived cellular contributions to tissue regeneration remain controversial. Bone marrow from DsRed-transgenic donors was transplanted into recipients to lineage-trace circulating cells after myocardial infarction (MI). SDF was delivered post-MI, and hearts were evaluated for recruitment and plasticity of bone marrowderived populations. SDF treatment improved ventricular function, border zone vessel density, and CD31+ cell frequency post-MI. Bone marrow-derived endothelial cells were observed; these cells arose through both cell fusion and transdifferentiation. Circulating cells also adopted cardiomyocyte fates, but such events were exceedingly rare and almost exclusively resulted from cell fusion. SDF did not significantly alter the proportion of circulating cells that adopted nonhematopoietic fates. Mechanistic insight into the governance of circulating cells is essential to realizing the full potential of cytokine therapies.
Introduction
The capacity of the adult mammalian heart to reconstitute lost cardiomyocytes, smooth muscle, and endothelial cells after myocardial infarction (MI) is limited. Yet, cardiac and other progenitor cells are increasingly identified and hold promising translational potential [1] [2] [3] [4] . Chemokines that attenuate ischemic damage to the heart via their angiogenic or regenerative effects are also attractive candidates for clinical translation [5, 6] . In fact, stromal cell-derived factor 1-alpha's (SDF) potent angiogenic and anti-apoptotic effects have led to testing in humans.
SDF-a crucial component of the hematopoietic nicherecruits endothelial progenitor cells as well as cells from the hematopoietic lineage from the bone marrow to the site of organ injury [5, 6] . However, significant controversy remains regarding the role that bone marrow-derived circulating cells play in post-MI myocardial repair, particularly whether they adopt non-hematopoietic fates [7] [8] [9] [10] [11] . Many scrutinize the proposed multi-potency and existence of hematopoietic cell transdifferentiation into cardiomyocytes and vascular cells [7, 9, 12] . Conversely, others support the plasticity of bone marrow-derived cells [1, 8, 10, 11, 13] . Despite enduring disagreement regarding the existence, functionality, and durability of bone marrow-derived cardiomyocytes, physicians continue to test bone marrow as a cellular therapy for the treatment of patients with acute MI and chronic ischemic cardiomyopathy [14] [15] [16] [17] [18] [19] [20] . Unfortunately, such studies often yield statistically significant-but clinically insignificant-results.
We investigated the fate of bone marrow cells recruited to injured myocardium by SDF. We lineage-traced the bone marrow and used florescent-activated cell sorting (FACS) and histology to evaluate (1) if bone marrow-derived cells contribute directly to the myocardium and (2) if SDF augments endogenous repair mechanisms via altering hematopoietic plasticity. Because of the demonstrated therapeutic efficacy of SDF, it is essential to analyze how SDF regulates circulating cell populations in order to pave the way for future therapies to leverage responsive circulating populations.
Methods
Bone Marrow Lineage-Tracing Mouse Model We used mice transgenic for DsRed (driven by the chicken β-actin promoter) [21] as bone marrow donors. C57Bl/6 mice or mice transgenic for eGFP (driven by the chicken β-actin promoter) on a C57Bl/6 background were used as recipients. All mice were given sterile food and autoclaved acidified water and housed under pathogen-free conditions. All experiments were approved by the Administrative Panel on Laboratory Animal Care at Stanford University (protocol 28921) and conform to the NIH guidelines. Two mouse strains were used as bone marrow recipients in this study: C57Bl/6 recipients and C57Bl/6-eGFP recipients. C57Bl/6 recipients were transplanted with C57Bl/6-DsRed bone marrow and randomized to one of three groups: sham surgery (N = 3), myocardial infarction with intramyocardial injection of PBS (phosphate-buffered saline, N = 7), or myocardial infarction with intramyocardial injection of SDF and subcutaneous injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) (N = 7). C57Bl/6-eGFP recipients were transplanted with C57Bl/6-DsRed bone marrow and were randomized into two groups: myocardial infarction with intramyocardial injection of PBS (N = 5) or myocardial infarction with intramyocardial injection of SDF and subcutaneous injection of GM-CSF (N = 5). At experimental endpoints, cardiac tissue was analyzed through histological sections or flow cytometry analysis.
Generation of Bone Marrow-Chimeric Mice Recipient C57Bl/6-or eGFP-transgenic mice were lethally irradiated with 10 Gy split-dose radiation in a cabinet X-ray irradiator (5 Gy the evening before transplantation and 5 Gy the morning of transplantation). After lysing erythrocytes, whole bone marrow cells (5 × 10 6 ) from DsRed-transgenic mice were retro-orbitally injected into recipient mice 4 h after the final dose of radiation.
Analysis of Chimerism Hematopoietic reconstitution was evaluated in peripheral blood 2 to 4 weeks after transplantation, prior to ligation of the left anterior descending coronary artery. One hundred microliters of peripheral blood was collected from the tail vein, and red blood cells were lysed. Peripheral blood mononuclear cells were stained with fluorochrome-conjugated antibodies against CD3, CD19, Mac-1, and Gr-1. Granulocytes were defined as CD3−, CD19−, Mac-1+, and Gr-1+ (Supplementary Fig. 1 ). Longterm hematopoietic stem cells were also assessed in transplanted recipients and phenotypically described as Lineage−, ckit+, Sca-1+, Slam+, Flt3−, and CD34− ( Supplementary Fig. 1 ). Flow cytometry was performed using a LSR II machine (BD Biosciences, San Jose, CA, USA), and FlowJo software (Flowjo LLC, Ashland, OR, USA) was used for data analysis.
Culture of Endothelial Progenitor Cells
Bone marrow mononuclear cells were isolated from the long bones of adult male mice by density centrifugation with Histopaque 1083 (Sigma-Aldrich, St. Louis, MO, USA), plated on vitronectincoated dishes, and cultured in endothelial basal medium-2 supplemented with EGM-2 SingleQuot (Lonza, Basel, Switzerland) containing human epidermal growth factor, fetal bovine serum, vascular endothelial growth factor, basic human fibroblast growth factor, recombinant human long R3 insulinlike growth factor-1, ascorbic acid, heparin, gentamicin, and amphotericin-B. The media were changed 24 h after plating to facilitate removal of non-adherent bone marrow mononuclear cells. Subsequent medium changes were performed every 48 h for a total of 7 days to select for the endothelial progenitor cell phenotype. This culture method selects for the early outgrowth population of endothelial progenitor cells.
Model of Acute Myocardial Infarction Myocardial infarction was induced using an established and highly reproducible model [22] . Briefly, mice were anesthetized in a 2-L induction chamber (VetEquip, CA, USA) and 3% isoflurane was continuously delivered. Mice were intubated endotracheally with a 20-gauge angiocatheter and subsequently connected to a mechanical ventilator (Hallowell EMC, Pittsfeild, MA USA); 2% isoflurane was maintained throughout the procedure. Buprenorphine (0.5 mg/kg) and carprofen (5 mg/kg) were administered for pain control. The heart was exposed through the left fourth intercostal space, and an 8-0 polypropylene suture was tied around the left anterior descending coronary artery midway between the left atrium and the ventricular apex. Mice randomized to the sham control group (n = 3) underwent thoracotomy without coronary ligation. The animals were randomized to two experimental groups (n = 13/group) and received three 20-μL intramyocardial injections within the border zone myocardium of either PBS (60 μL total) or SDF (6 μg/kg in 60 μL total, Anaspec, Fremont, CA, USA). Mice randomized to the SDF group also received one subcutaneous injection of recombinant mouse granulocyte/macrophage colony-stimulating factor (40 μg/ kg) (Genzyme, Cambridge, MA, USA). Our experimental design was based on previous work demonstrating a synergistic effect of GM-CSF and SDF therapies in treating ischemic injury from myocardial infarction [23] . Of note, our previous experience demonstrated no difference between the control groups of PBS alone and PBS with GM-CSF, indicating that GM-CSF only has a benefit when paired with SDF and has no angiogenic properties when used alone. For this reason, we did not include it as a negative control.
Echocardiography Assessment Left ventricular geometry and function (n = 20) were evaluated 2 weeks after MI with a high-resolution (30 MHz) Vevo 2100 transthoracic echocardiography system (VisualSonics, Toronto, Canada). Images were obtained through a parasternal short-axis view with Mmode ultrasound at the level of the papillary muscle and midway between the papillary muscle and the apex. Ejection fraction, fractional shortening, and internal ventricular dimensions were computed with the Vevo 770 standard measurement package. All analyses were performed by a single investigator blinded to the treatment assignment.
Langendorff Dissociation Mice were sedated in an isoflurane induction chamber, and their hearts were excised under inhaled anesthesia. The aorta was cannulated for anterograde coronary artery perfusion through the Langendorff system. The adult rat/ mouse cardiomyocyte isolation kit (Cat No. AC-7031 from Cellutron Life Technologies, Baltimore, MD, USA) was used to digest the heart. The heart was perfused with wash buffer for 4 min and then with collagenase for 10 min at a constant flow of 3 mL/min. The heart was subsequently minced and shaken for 5 min in 7 mL of collagenase solution. The resulting solution was then centrifuged for 1 min at 500 rpm to separate the cardiomyocytes and the supernatant. Cardiomyocytes were resuspended using a cell suspension buffer.
Fluorescent-Activated Cell Sorting and Analysis
The Langendorff procedure separates the cardiomyocytes (in the pellet) from the cardiac-associated small cells (in the supernatant). Both samples were stained with CD45-APC-cy7, CD31-Pecy7, and troponin-APC. Extracellular antigens were stained first. Cells were then treated with transcription factor buffer set (BD) and stained for intracellular troponin. Flow cytometry was performed with an Aria machine (BD). The supernatant was sorted with forward-scattered light (FSC)/ side-scattered light (SSC) voltages appropriate for hematopoietic cells whereas the pellet was sorted with FSC/SSC voltages appropriate for cardiomyocytes. FlowJo software was used for data analysis.
Immunohistochemistry and Histology Analyses At the study endpoint, a subset of animals was anesthetized and their hearts were explanted. Hearts were flushed with PBS, filledretrograde with Tissue-Plus optimal cutting temperature compound (Fisher Scientific, Hampton, NH, USA), frozen at − 80°C, and sectioned onto Superfrost Plus microscope slides (Fisher Scientific) using a Cryostar NX70 cyrostat (Thermo Scientific, Waltham, MA, USA) at 10-μm thickness. Next, the samples were fixed with 4% paraformaldehyde and blocked with 10% fetal bovine serum. Separate sections were stained for cardiac troponin (ab47003, Abcam, Cambridge, UK) and the Von Willebrand factor (Abcam ab11713). The antibodies were diluted at 1:200 in PBS and incubated for 2 h at 37°C. The sections were washed in PBS, and the appropriate secondary antibodies (Abcam) were applied at a dilution of 1:200 for 1-h incubation at 37°C. The slides were washed in PBS and counterstained for nuclei with NucBlue DAPI (4′,6-diamidino-2-phenylindole; ThermoFisher Scientific) following the manufacturer's protocol. Stained sections were imaged with a LSM 780 confocal microscope (Zeiss, Oberkochen, Germany). Vessel density was calculated using ImageJ software (v1.49, NIH).
Statistical Analysis Continuous variables are presented as means with corresponding standard errors, and categorical variables are presented as proportions. Differences between groups were assessed with the Student t test for independent samples. All tests were two-tailed, and a P value less than 0.05 was considered statistically significant. Statistical analyses were performed with Prism 6.0 (GraphPad, La Jolla, CA, USA).
Results

SDF Enhances Post-infarction Ventricular Function and
Vessel Density Consistent with previous reports, we observed that SDF significantly enhanced ventricular function after MI when delivered at the time of injury as compared to PBS. Three weeks after treatment, echocardiographic assessment demonstrated a significantly improved left ventricular ejection fraction (57.6 ± 5.0 vs. 41.9 ± 3.7%, P = 0.018) and fractional shortening (31.2 ± 3.5 vs. 21.1 ± 2.1%, P = 0.02) and a strong trend toward a reduction in left ventricular end systolic diameter (2.44 ± 0.21 vs. 2.96 ± 0.19 mm, P = 0.076) (Fig. 1a, b) . Histological evaluation of Von Willibrand factor (VWF) demonstrated increased vessel density in the border zone region of SDF-treated recipients compared with that of PBS-treated recipients (Fig. 1d, e) . Quantification of VWF signal confirmed this observed increase was statistically significant (P = 0.0002).
Successful Bone Marrow Transplantation Results in near 100% Multi-lineage Donor Chimerism To study whether circulating bone marrow cells contribute to myocardial repair and investigate how SDF treatment attenuates myocardial injury, we established a lineage-tracing model whereby the recipient bone marrow was replaced with bone marrow from DsRed-transgenic mice (Fig. 2a) . All mice survived the procedure, and 4 weeks after transplant, the total peripheral blood chimerism was 95 ± 1%. Granulocyte chimerism-a proxy for hematopoietic stem cell (HSC) chimerism [24] -was 99 ± 2% (Fig. 2b ) and strongly correlated with long-term HSC chimerism in the bone marrow (Supplemental Fig. 1A ). To confirm successful engraftment of non-HSC lineages, endothelial progenitor cells were isolated and cultured from the mouse bone marrow after transplant. Fluorescent microscopy of bone marrow smears and isolated endothelial progenitor cells demonstrated diffuse expression of DsRed (Fig. 2c, d ). The near 100% chimerism obtained with this model permits multilineage fate tracking of bone marrow cells with high sensitivity.
Circulating Bone Marrow Cells Contribute to Coronary Vessel Endothelium Post MI We then used the aforementioned model to trace the fate of circulating bone marrow cells before and after MI to investigate the endogenous repair mechanisms after ischemic injury. Because the plasticity of circulating BM cells remains controversial, we thought it necessary to evaluate the baseline recruitment and repair mechanisms post MI using this transplantation model. With flow cytometry, we categorized cells as hematopoietic (CD45+), endothelial (CD31+), or cardiomyocytes (troponin+); cells that additionally expressed DsRed originated from the bone (Figs. 3a and 4a ). After MI, the vast majority of bone marrow-derived cells found within the heart were hematopoietic (94.1 ± 0.3%) (Supplemental Fig. 1B) . The large influx of hematopoietic cells localized primarily to the area of myocardial injury (the anterolateral left ventricular wall) and decreased over time ( Supplemental Fig. 1C) .
The number of endothelial cells significantly decreased after MI (Fig. 3b) . Notably, DsRed+/CD31+ endothelial cells were observed in very small quantities in uninjured hearts. Myocardial injury, however, stimulated an increase in the proportion of bone marrow-derived endothelial cells (1.0 ± 0.2 vs. 0.2 ± 0.03%, P = 0.028) (Fig. 3c) . This increase in bone marrow-derived endothelial cells was spatially confined to the area of injury and infarct border zone (Fig. 3e) . Negligible numbers of bone marrow-derived endothelial cells were observed in the remote myocardium (Fig. 3f) . These data suggest myocardial ischemia stimulates bone marrow-derived vasculogenesis in the compromised area. However, the bone marrow minimally contributes to endothelial maintenance in the absence of injury.
Circulating Bone Marrow Cells Adopt Cardiomyocyte
Fates Post MI We then characterized the cardiomyocyte population in injured and uninjured hearts with flow cytometry. The plasticity of circulating bone marrowderived populations remains controversial; however, FACS analysis allows for high-throughput analysis of cardiomyocytes (troponin+), providing more accuracy to rare-occurring events that may be inaccurately accounted for with manual assessment. A small population of troponin+/DsRed+ cells was identified (0.046 ± 0.023% of troponin+ cells), thereby suggesting that bone marrow cells may adopt a cardiomyocyte phenotype (Fig. 4a) . Immunohistochemistry and confocal microscopy of cardiac tissue confirmed the rare presence of troponin+/ DsRed+ cells, but true sarcomeric structures were not clearly identifiable (Fig. 4e) . These bone marrow-derived cardiomyocytes were observed outside the area of injury, and the number of these rare cells was not altered by myocardial injury (Fig. 4c) . The vast majority of DsRed+/troponin+ cells co-expressed GFP (95.2 ± 1.0%) (Fig. 4d) . Therefore, bone marrow-derived cardiomyocytes are primarily generated from fusion with existing GFP+ cardiomyocytes. A very small population of GFP−/DsRed+ cells was also identified (0.0029 ± 0.0014% of troponin+ cells) and does suggest the potential-though rare-for circulating bone marrow cells to form de novo cardiomyocytes. Histologic examination of sorted DsRed+ and GFP+/DsRed+ cells confirmed the existence of troponin+ fusion and de novo formation cell types (Fig. 4f) . Whereas de novo formation was exceedingly rare among bone marrowderived cardiomyocytes, this lineage-tracing analysis demonstrated bone marrow-derived vascular endothelial cells do arise from de novo generation. However, rates of cell fusion remained greater than de novo generation among the bone marrow-derived endothelial population (Fig. 3d) .
SDF Improves Capillary Density Without Increasing the Direct Contribution from Bone Marrow Cells
To assess if the baseline contribution of circulating cells is augmented by SDF treatment, we performed the same FACS and histological analyses on animals treated with SDF at the time of ischemic injury. A significant increase in the frequency of CD31+ cells was noted in SDF-treated hearts compared to that of PBStreated hearts (Fig. 5a ). The increase in CD31+ cells correlated with an increase in vessel density in the infarct border zone (Fig. 1c, d ). These observations confirm the pro-angiogenic properties of SDF. However, lineage tracing demonstrated that SDF did not alter the proportion of endothelial cells that were derived from the bone marrow (Fig. 5b) , indicating that SDF likely affects angiogenesis through sprouting of preexisting endothelium rather than through bone marrow-mediated vasculogenesis.
Functional Benefits of SDF Do Not Result from Expansion of the Bone Marrow-Derived Cardiomyocyte Population
After MI, SDF administration did not alter the proportion of bone marrow-derived (DsRed+) cardiomyocytes (Fig. 5c ).
Discussion
The delivery of cytokines to augment endogenous repair processes is increasingly studied as a potential therapeutic for ischemic heart disease. SDF, a molecule expressed in response to ischemia and with known pro-angiogenic properties, is a potent chemokine for endothelial progenitor cells. Similar to previous reports [21, 23, [25] [26] [27] the bone marrow if models with ≤ 50% chimerism, such as parabiosis, are utilized [7, 11] . Additionally, manual quantification of an event that may occur at a frequency as low as 0.001% is prone to error or miscalculation. FACS analysis permitted a higher resolution for detecting rare-occurring events that result from endogenous repair mechanisms post MI. We chose three cell subtypes to evaluate, and they were described by their phenotypic expression of CD31, CD45, and troponin. These are markers of mature populations and do not delineate tissue-resident or circulating stem cells such as the endothelial progenitor cell. In addition, there is a variety of cell subtypes in the bone marrow such as fibroblasts and mesenchymal cells that we have not evaluated in this model. However, we believe our data captured some of the crucial cellular components affected by SDF, and laid the foundation for further analysis of cell types (mature or progenitor) that may be involved in post infarction myocardial repair.
In agreement with other groups [9, 11, 28] , we observed that the clear majority of circulating cells that engraft into injured myocardium retain hematopoietic markers and phenotypes. This influx and engraftment of bone marrow-derived circulating cells into injured myocardium are transient and are consistent with the post-infarction inflammatory response [9] . However, our studies also confirmed the ability of bone marrow-derived circulating cells to adopt non-hematopoietic fates within mouse hearts subjected to a MI, albeit at low frequencies.
A small population of vascular endothelial cells originated from the bone marrow in our study. This observation is in accord with prior evidence that bone marrowderived cells form satellite reservoirs in the stroma of distant organs or home to remote areas of injury to reconstitute vascular endothelium [11, 13, 29] . Myocardial injury stimulated the repopulation of endothelial cells by bone marrow-derived cells. After MI, bone marrow-derived endothelial cells primarily localized to the infarct border zone and area of injury. Additionally, lineage tracing demonstrated that a large proportion of bone marrow-derived endothelial cells arose from de novo formation. These findings indicate that postnatal neovascularization does not rely exclusively on sprouting from preexisting blood vessels [29] . Rather, circulating cells from the bone marrow may also incorporate into and thus contribute to postnatal reparative vasculogenesis [11, 13, 29] .
Treatment with SDF increased the total number of bone marrow-derived endothelial cells in the heart. However, it did not increase the percent of endothelial cells that were derived from the bone marrow. Thus, SDF recruits bone marrow-derived cells to the heart after MI, but it does not increase the frequency at which these circulating bone marrow cells adopt non-hematopoietic fates. The observed increase in vessel density after treatment with SDF may be due to the recruitment of progenitor cells from the bone marrow which promote endogenous growth of preexisting vessels via paracrine signaling, rather than via a direct contribution to the endothelium. Alternatively, we may have not observed a significant population of bone marrow-derived endothelial cells if bone marrow transplant failed to engraft late outgrowth endothelial progenitor cells; in our study, we only confirmed the presence of the early outgrowth population.
Unexpectedly, we observed a CD31+ endothelial population derived from fusion events of circulating bone marrow (DsRed+) and endogenous cardiac tissue (GFP+). Although the mechanism of endothelial fusion events is not fully described, it has been observed that dendritic cells as well as monocytes can fuse with endothelial cells [30, 31] . We believe our study could be an excellent lineage-tracing model to further investigate this phenomenon in vivo.
We also observed that bone marrow-derived cells may also assume a cardiomyocyte fate within the heart, although to an even lesser extent than the aforementioned endothelial cell fate. Furthermore, the bone marrow-derived cardiomyocytes identified in tissue sections did not appear to have a mature sarcomeric structure. Interestingly, this rare event was not stimulated by myocardial injury; the same frequency of bone marrow-derived cardiomyocytes was observed in both infarcted and non-infarcted hearts. The rare bone marrow-derived cardiomyocytes were also observed as isolated cells, without the appearance of clonal expansion. Unlike reparative vasculogenesis, the endogenous contribution of the bone marrow to cardiomyocyte reconstitution may therefore be limited to cell maintenance rather than injury response [32] [33] [34] .
The apparent plasticity of bone marrow cells to form cardiomyocytes was almost entirely attributable to cell fusion rather than transdifferentiation. Importantly, the experiments performed in the present investigation utilized whole bone marrow transplant rather than purified hematopoietic stem cell transplant to generate chimeric recipients. Therefore, we hypothesize it is not the hematopoietic stem cell, but rather a different progenitor population within the heterogeneous bone marrow pool that is responsible for de novo generation of cardiomyocytes. In addition, the functionality and true sarcomeric structure of these rare-occurring populations requires further investigation. The limited contribution of the bone marrow to cardiomyocyte reconstitution underscores the inadequate improvements in ventricular function reported in clinical trials of intramyocardial or intracoronary bone marrow cell administration [14] [15] [16] [17] [18] [19] .
Treatment with exogenous SDF failed to increase the percentage of bone marrow-derived cardiomyocytes. Because we used an acute MI model, it is possible that additional benefits of SDF in preserving ventricular function are due to its direct anti-apoptotic signaling [25] . In models of chronic ischemic cardiomyopathy, SDF improves vessel density and decreases scar size [35, 36] . Because SDF did not augment the formation of bone marrowderived cardiomyocytes in acute ischemia, its mechanism of repair in chronic heart failure requires further study, but is unlikely mediated via stimulation of bone marrow-derived de novo vasculogenesis and cardiomyogenesis.
Here, we demonstrate that SDF, a potent chemokine of progenitor cells within the bone marrow, improved myocardial function but did not alter the plasticity of circulating bone marrow cells. Rather, the recruited bone marrow cells likely attenuate myocardial injury via paracrine signaling [37] . Also, the direct anti-apoptopic effect of SDF is well-described and likely limits cardiomyocyte loss [25] . Identification of the signaling pathway that regulates bone marrow cell transdifferentiation and fusion, as well as the specific cell that undergoes such transformation, is essential to understand how bone marrow cells and therapeutic chemokines may be most efficiently utilized for myocardial repair. 
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